PTX 8.89% 4.1¢ prescient therapeutics limited

Morning mate, Going by the quarterly PTX-200 is progressing...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 3,872 Posts.
    lightbulb Created with Sketch. 3205
    Morning mate,

    Going by the quarterly PTX-200 is progressing well. The trial has progress to a higher dose level of 45 mg/m2 as reported in April. Given that PTX reported on the dosing levels at 35 mg/m2 back in April I'm going to assume the increased dosing had probably commenced by late April or early May.

    The recent quarterly says further updates in relations to ptx-200 in the coming months so I'm assuming the next update will be a lot sooner than December.



    "During the quarter Prescient’s targeted therapy studies for PTX-100 and PTX-200 continue to make excellent progress and enrol patients with no safety issues reported by investigators. On 23 April 2021 Prescient reported on the Phase 1b clinical study of PTX-200 and cytarabine in patients with acute myeloid leukemia (AML) has successfully completed the second cohort at 35 mg/m2 under a modified study protocol, with no safety or toxicity issues observed. The study is now progressing through the higher dose level of 45 mg/m2 and Prescient looks forward to providing updates in coming months."

    Cheers.
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
(20min delay)
Last
4.1¢
Change
-0.004(8.89%)
Mkt cap ! $33.01M
Open High Low Value Volume
4.4¢ 4.4¢ 4.1¢ $43.46K 1.014M

Buyers (Bids)

No. Vol. Price($)
9 419623 4.1¢
 

Sellers (Offers)

Price($) Vol. No.
4.3¢ 568217 2
View Market Depth
Last trade - 16.10pm 31/10/2024 (20 minute delay) ?
PTX (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.